Spectrum initiated at Cantor Fitzgerald

Spectrum initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Alethia Young started Spectrum Pharmaceuticals with an Overweight rating and $19 price target. The analyst has confidence that poziotinib can show a differentiated response in the pivotal Phase 2 study and believes the value for Rolontis is being underappreciated. This “provides some floor to the valuation,” Young tells investors in a research note. With no approved drugs for exon 20, the analyst thinks the efficacy bar is relatively low.

https://thefly.com/landingPageNews.php?id=2860771